Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ6VD5)

• Drug Name: M-518101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Phase 3	[1]
Psoriasis vulgaris	EA90	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 16122802
  TTD Drug ID: DMZ6VD5

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase (PDE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NM-702	DMDJLY9	Angina pectoris	BA40	Phase 3	[3]
Piroximone	DMQXJDM	Cardiac failure	BD10-BD13	Discontinued in Phase 3	[4]
AA-2379	DM78623	Inflammation	1A00-CA43.1	Discontinued in Phase 2	[5]
HN-10200	DMYJ1ZB	Cardiac failure	BD10-BD13	Discontinued in Phase 2	[6]
TIBENELAST	DMYH2PU	Asthma	CA23	Discontinued in Phase 2	[7]
ALBIFYLLINE	DMVBKLO	Sepsis	1G40-1G41	Discontinued in Phase 1	[8]
Sch-45752	DME9Q3V	Asthma	CA23	Terminated	[9]
Isomazole	DM4YJ2W	Asthma	CA23	Terminated	[10]
BBB-022	DMITV4F	Cerebrovascular ischaemia	8B1Z	Terminated	[11]
JTT-608	DMZBNHC	Diabetic complication	5A2Y	Terminated	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase (PDE)	TTUST1O	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT01989429) Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients. U.S. National Institutes of Health.
• [3] The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
• [4] Circulatory effects of the PDE-inhibitors piroximone and enoximone. Br J Clin Pharmacol. 1993 Oct;36(4):309-14.
• [5] Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action. Agents Actions. 1989 Nov;28(3-4):248-55.
• [6] HN-10200 causes endothelium-independent relaxations in isolated canine arteries. Cardiovasc Drugs Ther. 1992 Apr;6(2):159-65.
• [7] Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels. Pharmacology. 1993;46(3):142-7.
• [8] Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 1995 Jan;25(1):147-53.
• [9] SCH 45752--an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J Antibiot (Tokyo). 1993 Feb;46(2):207-13.
• [10] Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol. 1991 Sep;18(3):386-97.
• [11] Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400.
• [12] JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol. 1999 Feb 12;367(1):91-9.